S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Compare Vaccine Stocks

Enter up to ten stock symbols separated by a comma or space (ex. GILD,JNJ,MRNA,NVAX,PFE).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PFE
Pfizer
$52.79
-2.3%
$54.89
$33.36
$61.71
$296.30B0.6937.95 million shs41.06 million shs
MRNA
Moderna
$160.07
-4.4%
$254.17
$117.34
$497.49
$64.90B1.229.83 million shs11.77 million shs
GILD
Gilead Sciences
$68.51
+1.0%
$70.76
$61.39
$74.12
$85.94B0.348.42 million shs14.83 million shs
JNJ
Johnson & Johnson
$164.87
-0.2%
$166.31
$151.47
$179.92
$434.04B0.747.18 million shs10.55 million shs
NVAX
Novavax
$84.65
-6.3%
$161.55
$84.55
$331.68
$6.40B1.176.37 million shs5.72 million shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
PFE
Pfizer
3.50 of 5 Stars
2.34.84.22.53.8
MRNA
Moderna
2.76 of 5 Stars
4.14.70.02.52.5
GILD
Gilead Sciences
3.32 of 5 Stars
3.35.04.21.72.5
JNJ
Johnson & Johnson
2.81 of 5 Stars
2.44.44.22.50.6
NVAX
Novavax
2.13 of 5 Stars
3.45.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PFE
Pfizer
2.55
Buy$57.428.77% Upside
MRNA
Moderna
2.29
Hold$247.6354.70% Upside
GILD
Gilead Sciences
2.57
Buy$79.1815.58% Upside
JNJ
Johnson & Johnson
2.70
Buy$187.4013.67% Upside
NVAX
Novavax
2.71
Buy$245.83190.41% Upside

Current Analyst Ratings

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/21/2022
MRNA
Moderna
UBS Group
Initiated CoverageNeutral$221.00
1/21/2022
MRNA
Moderna
Bank of America
UpgradeUnderperform ➝ Neutral$135.00 ➝ $180.00
1/21/2022
NVAX
Novavax
Cowen
Initiated CoverageOutperform$150.00
1/18/2022
MRNA
Moderna
Morgan Stanley
Boost Price TargetEqual Weight$313.00 ➝ $315.00
1/18/2022
GILD
Gilead Sciences
Morgan Stanley
Lower Price TargetEqual Weight$74.00 ➝ $72.00
1/14/2022
PFE
Pfizer
BMO Capital Markets
Boost Price Target$60.00 ➝ $76.00
1/14/2022
GILD
Gilead Sciences
BMO Capital Markets
Initiated CoverageBuy$85.00
1/11/2022
PFE
Pfizer
Barclays
Set Price Target$54.00
1/10/2022
PFE
Pfizer
The Goldman Sachs Group
Set Price Target$51.00
1/7/2022
PFE
Pfizer
Wells Fargo & Company
Boost Price TargetOverweight$60.00 ➝ $65.00
1/6/2022
MRNA
Moderna
Argus
Lower Price Target$420.00 ➝ $350.00
(Data available from 1/22/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PFE
Pfizer
$41.91B7.07$2.99 per share17.67$11.42 per share4.62
MRNA
Moderna
$803.40M80.78N/AN/A$6.47 per share24.74
GILD
Gilead Sciences
$24.69B3.48$8.10 per share8.46$14.54 per share4.71
JNJ
Johnson & Johnson
$82.58B5.26$10.74 per share15.35$24.04 per share6.86
NVAX
Novavax
$475.60M13.46N/AN/A$9.85 per share8.59

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PFE
Pfizer
$9.62B$3.3615.718.650.7227.66%30.70%12.92%2/8/2022 (Confirmed)
MRNA
Moderna
-$747.06M$16.319.816.180.2559.69%121.61%49.46%2/24/2022 (Estimated)
GILD
Gilead Sciences
$123M$5.8611.6910.120.7126.91%56.59%16.36%2/1/2022 (Confirmed)
JNJ
Johnson & Johnson
$14.71B$6.6924.6416.042.3219.55%37.90%14.50%1/25/2022 (Confirmed)
NVAX
Novavax
-$418.26M-$14.81N/A3.18N/A-89.31%-149.66%-45.23%3/7/2022 (Estimated)

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/8/2022N/A
PFE
Pfizer
$0.88N/A-$0.88N/AN/AN/A  
2/1/2022N/A
GILD
Gilead Sciences
$1.47N/A-$1.47N/AN/AN/A  
1/25/2022N/A
JNJ
Johnson & Johnson
$2.12N/A-$2.12N/AN/AN/A  
11/4/20219/30/2021
MRNA
Moderna
$9.49$7.70-$1.79$7.70$6.29 billion$4.97 billion    
11/4/20219/30/2021
NVAX
Novavax
-$4.04-$4.31-$0.27-$4.31$347.34 million$178.80 million    
11/2/20219/30/2021
PFE
Pfizer
$1.08$1.34+$0.26$1.26$22.82 billion$24.09 billion    
10/28/20219/30/2021
GILD
Gilead Sciences
$1.72$2.65+$0.93$3.25$6.31 billion$7.42 billion    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PFE
Pfizer
$1.562.96%+14.71%46.43%12 Years
MRNA
Moderna
N/AN/AN/AN/AN/A
GILD
Gilead Sciences
$2.844.15%+24.56%48.46%6 Years
JNJ
Johnson & Johnson
$4.242.57%+18.36%63.38%60 Years
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest ARAV, IMMP, ETTX, ELTP, and TLSA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/4/2022
JNJ
Johnson & Johnson
quarterly$1.062.47%2/18/20222/22/20223/8/2022
12/10/2021
PFE
Pfizer
quarterly$0.403.05%1/27/20221/28/20223/4/2022
10/28/2021
GILD
Gilead Sciences
Quarterly$0.714.38%12/14/202112/15/202112/30/2021
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PFE
Pfizer
0.48
1.39
1.18
MRNA
Moderna
0.02
1.35
1.25
GILD
Gilead Sciences
1.22
1.37
1.20
JNJ
Johnson & Johnson
0.43
1.34
1.11
NVAX
Novavax
0.70
1.24
1.24

Ownership

Institutional Ownership

CompanyInstitutional Ownership
PFE
Pfizer
64.88%
MRNA
Moderna
59.11%
GILD
Gilead Sciences
78.67%
JNJ
Johnson & Johnson
67.48%
NVAX
Novavax
48.62%

Insider Ownership

CompanyInsider Ownership
PFE
Pfizer
0.05%
MRNA
Moderna
19.4%
GILD
Gilead Sciences
0.12%
JNJ
Johnson & Johnson
0.3%
NVAX
Novavax
2.1%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
PFE
Pfizer
78,5005.61 billion5.61 billionOptionable
MRNA
Moderna
1,300405.45 million326.79 millionOptionable
GILD
Gilead Sciences
13,6001.25 billion1.25 billionOptionable
JNJ
Johnson & Johnson
134,5002.63 billion2.62 billionOptionable
NVAX
Novavax
79175.61 million74.02 millionOptionable

ARAV, IMMP, ETTX, ELTP, and TLSA Headlines

SourceHeadline
My Kingdom for a Booster Shot: Hiccups Are Yet Another Vaccine Trial Hassle - MedPage TodayMy Kingdom for a Booster Shot: Hiccups Are Yet Another Vaccine Trial Hassle - MedPage Today
medpagetoday.com - January 22 at 1:46 PM
2 Growth Stocks That Could Take Off in February - Motley Fool2 Growth Stocks That Could Take Off in February - Motley Fool
fool.com - January 21 at 3:15 PM
Why Novavax is the jab the unvaxxed have been waiting for - Gold Coast BulletinWhy Novavax is the jab the unvaxxed have been waiting for - Gold Coast Bulletin
goldcoastbulletin.com.au - January 21 at 3:15 PM
Worldwide Adoption of Novavax Vaccines Makes It a WinnerWorldwide Adoption of Novavax Vaccines Makes It a Winner
investorplace.com - January 21 at 3:01 PM
Novavax (NASDAQ:NVAX) Receives New Coverage from Analysts at CowenNovavax (NASDAQ:NVAX) Receives New Coverage from Analysts at Cowen
americanbankingnews.com - January 21 at 10:23 AM
Novavax (NASDAQ:NVAX) Now Covered by Analysts at CowenNovavax (NASDAQ:NVAX) Now Covered by Analysts at Cowen
marketbeat.com - January 21 at 7:34 AM
Novavax COVID-19 vaccine provisionally approved for use in Australia - SBSNovavax COVID-19 vaccine provisionally approved for use in Australia - SBS
sbs.com.au - January 21 at 3:32 AM
Novavax Stock is in a Tough Spot, but its Fortunes Could ImproveNovavax Stock is in a Tough Spot, but its Fortunes Could Improve
investorplace.com - January 20 at 6:04 PM
Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week - NasdaqWhy BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week - Nasdaq
nasdaq.com - January 20 at 5:31 PM
What difference will Novavax make in Australias fight against COVID? - ABC NewsWhat difference will Novavax make in Australia's fight against COVID? - ABC News
abc.net.au - January 20 at 5:31 PM
Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This WeekWhy BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week
finance.yahoo.com - January 20 at 5:31 PM
Novavax Is Oversold, Time To Buy for Future GrowthNovavax Is Oversold, Time To Buy for Future Growth
investorplace.com - January 20 at 5:00 PM
Novavax Is Worth 77% More Over the Next 2 YearsNovavax Is Worth 77% More Over the Next 2 Years
investorplace.com - January 20 at 11:01 AM
Why Novavax Stock Is Already Down 30% This YearWhy Novavax Stock Is Already Down 30% This Year
forbes.com - January 20 at 8:48 AM
Novavax Stock May Not Be This Cheap For LongNovavax Stock May Not Be This Cheap For Long
investorplace.com - January 20 at 6:19 AM
Novavax (NASDAQ:NVAX) Sets New 52-Week Low at $91.70Novavax (NASDAQ:NVAX) Sets New 52-Week Low at $91.70
americanbankingnews.com - January 20 at 4:02 AM
Novavax’s COVID-19 vaccine gains momentum with Australia approval - FortuneNovavax’s COVID-19 vaccine gains momentum with Australia approval - Fortune
fortune.com - January 20 at 2:24 AM
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine - Kilgore News HeraldAustralia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine - Kilgore News Herald
kilgorenewsherald.com - January 19 at 9:24 PM
TGA approves Novavax COVID vaccine, anti-viral pills to treat disease in vulnerable patients - ABC NewsTGA approves Novavax COVID vaccine, anti-viral pills to treat disease in vulnerable patients - ABC News
abc.net.au - January 19 at 9:24 PM
Could Novavax Go Parabolic? - NasdaqCould Novavax Go Parabolic? - Nasdaq
nasdaq.com - January 19 at 11:23 AM
Canada within weeks of deciding on Novavax, Medicago vaccines - CTV NewsCanada within 'weeks' of deciding on Novavax, Medicago vaccines - CTV News
ctvnews.ca - January 18 at 6:12 PM
Novavax (NASDAQ:NVAX)  Shares Down 7.4% Novavax (NASDAQ:NVAX) Shares Down 7.4%
americanbankingnews.com - January 18 at 2:48 PM
Heres Some Good News for Novavax That Investors Are Overlooking - Motley FoolHere's Some Good News for Novavax That Investors Are Overlooking - Motley Fool
fool.com - January 18 at 8:02 AM
Heres Some Good News for Novavax That Investors Are OverlookingHere's Some Good News for Novavax That Investors Are Overlooking
finance.yahoo.com - January 18 at 8:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.